+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neuropathic Pain Drug Market - Global Forecast 2026-2032- Product Image
Neuropathic Pain Drug Market - Global Forecast 2026-2032- Product Image
New

Neuropathic Pain Drug Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 180 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968619
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The neuropathic pain drug market is undergoing significant transformation, with senior stakeholders facing rapid shifts in clinical protocols, evolving policies, and growing commercial complexity. Proactive strategy and informed decision-making are essential for organizations aiming to maintain competitive advantage.

Market Snapshot: Neuropathic Pain Drug Market Growth and Dynamics

The Neuropathic Pain Drug Market is forecast to grow from USD 6.93 billion in 2025 to USD 7.36 billion in 2026, on track to reach USD 11.95 billion by 2032 with a CAGR of 8.10%. Growth is rooted in advanced clinical methodologies, new reimbursement models, and heightened demand for therapies that deliver measurable, real-world outcomes. This environment requires agile adjustments to evolving benchmarks in both operational and clinical value propositions.

Scope & Segmentation: Neuropathic Pain Drug Market Segments and Differentiators

  • Product Classes: Anticonvulsants such as carbamazepine, gabapentin, lamotrigine, and pregabalin; antidepressants including serotonin-norepinephrine reuptake inhibitors and tricyclics (duloxetine, venlafaxine, amitriptyline, nortriptyline); opioid options like tapentadol and tramadol; and topical agents encompassing capsaicin, diclofenac gel, and lidocaine patch. Each product class shapes clinical strategy and access considerations.
  • Routes of Administration: Intravenous, oral, topical, and transdermal delivery facilitate diverse efficacy profiles and patient adherence strategies, promoting individualized therapeutic approaches.
  • Clinical Indications: Coverage includes chemotherapy-induced neuropathy, diabetic neuropathy, HIV-associated neuropathy, and post-herpetic neuralgia. Each indication requires tailored clinical validation and market access positioning.
  • Distribution Channels: Hospitals, retail pharmacies, and specialty clinics impact market penetration, prescribing behavior, and inclusion in clinical guidelines.
  • Global Regions: The analysis extends to the Americas, Europe, Middle East & Africa, and Asia-Pacific, with focused attention on regulatory frameworks, payer roles, and dynamic health infrastructure. Regional variety in policy and technology adoption informs localized strategy development.

Key Takeaways: Strategic Insights for Senior Leadership

  • Ongoing innovation in drug mechanisms and delivery technologies is influencing therapeutic options, allowing differentiation in highly competitive segments.
  • Healthcare systems and payers are demanding stronger comparative data and clear impacts on patient quality of life, driving a need for outcome-focused communication and evidence generation.
  • Greater emphasis on non-opioid and multimodal treatments is reflected in updated prescribing guidelines and increased safety requirements, accelerating strategic portfolio evolution.
  • Optimized product-channel alignment and targeted clinical education support successful guideline adoption and promote long-term market opportunities across varying regional contexts.
  • Increased adoption of digital health tools and patient-reported metrics enables enhanced differentiation and shapes reimbursement pathways for advanced therapies.
  • Regional strategies that leverage robust clinical data, effective supply chain logistics, and appropriate commercial partnerships are crucial to address disparities and expand market footprint globally.

Tariff Impact: Navigating Trade Pressures and Supply Chain Adaptation

Changing global trade policies and tariff structures are altering the sourcing and distribution of active pharmaceutical ingredients and finished neuropathic pain drugs. Market participants are mitigating these impacts by diversifying suppliers and increasing investment in localized manufacturing. Transparent sourcing processes and flexible contract management are essential for maintaining uninterrupted supply during logistics disruptions. Scenario planning and adaptive supply chain models are becoming fundamental to ensure continued patient access across regulated markets.

Methodology & Data Sources

This report synthesizes current clinical sources, up-to-date regulations, and targeted expert interviews. Evidence is drawn from peer-reviewed research, policy analysis, and direct perspectives from clinicians, payers, and procurement professionals to deliver actionable insights for market leadership.

Why This Report Matters

  • Enables data-informed product pipeline strategy, evidence planning, and regulatory alignment to match evolving market demands.
  • Clarifies regional regulatory pathways, payer impacts, and distribution channel dynamics, providing critical direction for portfolio expansion and successful commercialization.
  • Supports effective supply chain resilience and operational flexibility in the face of shifting tariff and international trade dynamics.

Conclusion

Success in the neuropathic pain drug market depends on evidence-driven decisions, agile planning, and alignment with stakeholder priorities. Forward-thinking organizations will realize greater stability and stronger growth through these strategies.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Neuropathic Pain Drug Market, by Product Type
8.1. Anticonvulsants
8.1.1. Carbamazepine
8.1.2. Gabapentin
8.1.3. Lamotrigine
8.1.4. Pregabalin
8.2. Antidepressants
8.2.1. SNRIs
8.2.1.1. Duloxetine
8.2.1.2. Venlafaxine
8.2.2. TCAs
8.2.2.1. Amitriptyline
8.2.2.2. Nortriptyline
8.3. Opioids
8.3.1. Tapentadol
8.3.2. Tramadol
8.4. Topical Agents
8.4.1. Capsaicin
8.4.2. Diclofenac Gel
8.4.3. Lidocaine Patch
9. Neuropathic Pain Drug Market, by Route Of Administration
9.1. Intravenous
9.2. Oral
9.3. Topical
9.4. Transdermal
10. Neuropathic Pain Drug Market, by Indication
10.1. Chemotherapy-Induced Neuropathy
10.2. Diabetic Neuropathy
10.3. HIV-Associated Neuropathy
10.4. Post-Herpetic Neuralgia
11. Neuropathic Pain Drug Market, by Distribution Channel
11.1. Hospitals Pharmacy
11.2. Retail Pharmacies
11.3. Specialty Clinics
12. Neuropathic Pain Drug Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Neuropathic Pain Drug Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Neuropathic Pain Drug Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Neuropathic Pain Drug Market
16. China Neuropathic Pain Drug Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. AcelRx Therapeutics, Inc.
17.6. Bausch Health Companies Inc.
17.7. Eli Lilly and Company
17.8. Endo International plc
17.9. Grünenthal GmbH
17.10. Grünenthal GmbH
17.11. Hikma Pharmaceuticals PLC
17.12. Mylan N.V.
17.13. Novartis AG
17.14. Pfizer Inc.
17.15. Sanofi S.A.
17.16. Teva Pharmaceutical Industries Ltd.
List of Figures
FIGURE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CARBAMAZEPINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GABAPENTIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LAMOTRIGINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY PREGABALIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY NORTRIPTYLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TAPENTADOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRAMADOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CAPSAICIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DICLOFENAC GEL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY LIDOCAINE PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY CHEMOTHERAPY-INDUCED NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HIV-ASSOCIATED NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY POST-HERPETIC NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY HOSPITALS PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 109. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 110. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 111. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 112. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 113. AMERICAS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 119. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 120. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 121. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 122. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 124. NORTH AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 129. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 130. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 131. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 132. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 133. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. LATIN AMERICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 149. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 150. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 151. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 152. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 153. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 154. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 155. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 157. EUROPE NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 160. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 161. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 162. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 163. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 164. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 165. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 166. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 167. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 168. MIDDLE EAST NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 169. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 171. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 172. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 173. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 174. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 175. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 176. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 177. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 179. AFRICA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 182. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 183. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 184. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 185. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 186. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 187. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 188. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 190. ASIA-PACIFIC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 191. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 192. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 194. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 195. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 196. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 197. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 198. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 199. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 200. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 202. ASEAN NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 203. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 204. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 205. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 206. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 207. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 208. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 209. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 210. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 211. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 213. GCC NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 226. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 227. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 228. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 229. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 230. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 231. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 232. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 233. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 234. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 235. BRICS NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 237. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 238. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 239. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 240. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 241. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 242. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 243. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 244. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 245. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 246. G7 NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 248. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 249. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 250. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 251. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 252. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 253. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 254. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 255. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 256. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 257. NATO NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 258. GLOBAL NEUROPATHIC PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 261. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 262. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 263. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 264. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 265. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 266. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 267. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 268. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 269. UNITED STATES NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 270. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 271. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 272. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
TABLE 273. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
TABLE 274. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
TABLE 275. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
TABLE 276. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY OPIOIDS, 2018-2032 (USD MILLION)
TABLE 277. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY TOPICAL AGENTS, 2018-2032 (USD MILLION)
TABLE 278. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 279. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 280. CHINA NEUROPATHIC PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Neuropathic Pain Drug market report include:
  • AcelRx Therapeutics, Inc.
  • Bausch Health Companies Inc.
  • Eli Lilly and Company
  • Endo International plc
  • Grünenthal GmbH
  • Grünenthal GmbH
  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages180
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 7.36 Billion
Forecasted Market Value ( USD ) by 2032 $ 11.95 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

Diabetic Neuropathic Pain Market Report and Forecast 2025-2034 - Product Image

Diabetic Neuropathic Pain Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Peripheral Neuropathic Pain Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Application, Distribution Channel, and Region, 2025-2035 - Product Image

Peripheral Neuropathic Pain Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, Application, Distribution Channel, and Region, 2025-2035

  • Report
  • Global
From
Diabetic Neuropathic Pain Market - A Global and Regional Analysis: Focus on Type, Distribution Channel, and Region, 2025-2035 - Product Image

Diabetic Neuropathic Pain Market - A Global and Regional Analysis: Focus on Type, Distribution Channel, and Region, 2025-2035

  • Report
  • Global
From
Diabetic Neuropathic Pain Drug Pipeline Analysis Report 2025 - Product Image

Diabetic Neuropathic Pain Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Neuropathic Pain Market - Global Strategic Business Report - Product Image

Neuropathic Pain Market - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From

About the Neuropathic Pain Drug Market

The Neuropathic Pain Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neuropathic pain drugs are used to treat chronic pain caused by nerve damage, such as diabetic neuropathy, postherpetic neuralgia, and trigeminal neuralgia. These drugs are typically divided into two categories: anticonvulsants and antidepressants. Anticonvulsants are used to reduce the intensity of nerve pain, while antidepressants are used to reduce the frequency of nerve pain. Commonly prescribed neuropathic pain drugs include pregabalin, gabapentin, duloxetine, and amitriptyline. Some companies in the Neuropathic Pain Drug market include Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.